The company's gamma-delta T cells (GDT cells) are more efficient at killing tumor cells and more resistant to tumor escape mechanisms in solid tumors than more traditionally used alpha-beta T cells. GDT cells can be produced using blood from healthy donors in a process called allogenic cell transfer, according to the company. Furthermore, GDT cells only target tumor cells for which they have been engineered.

Kiromic submits 2 IND applications to FDA
Kiromic BioPharma has submitted two investigational new drug (IND) applications to the U.S. Food and Drug Administration (FDA) for its programmed cell...